SCHEMBL3311275

SCHEMBL3311275

CC(C)(C)[Si](Oc1ccc2c(C(=O)O)cccc2c1)(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.47
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
CDC25B P30305 4/20 0.45
TBXAS1 P24557 1/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
KDR P35968 4/20 0.37
AURKA O14965 2/20 0.37
MET P08581 2/20 0.37
TEK Q02763 2/20 0.37
LCK P06239 1/20 0.37
HSD17B10 Q99714 1/20 0.37
AURKB Q96GD4 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15997742 0.78 TBXAS1 (0.38) TBXAS1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7259643 0.78 KDM4E (0.37) KDM4EALDH1A1HPGDLCKHSD17B10
SCHEMBL9020526 0.77 KDM4E (0.49) KDM4EALDH1A1HPGDRAB9AMAPT
SCHEMBL31613816 0.75 CDC25B (0.64) PTPN1NR4A1NR4A2NR4A3CDC25B
SCHEMBL2510203 0.75 CDC25B (0.64) PTPN1NR4A1NR4A2NR4A3CDC25B
SCHEMBL176855 0.74 PRKAG1 (0.45) KDM4ESMN1; SMN2
SCHEMBL12919164 0.74 CA1 (0.46) NR4A1NR4A2NR4A3HPGDHSD17B10
SCHEMBL22559500 0.73 KDM4E (0.33) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL9043929 0.73 CYP19A1 (0.44) KDM4EALDH1A1HPGDLCKNPC1
Hydrochloric Acid SCHEMBL6432261 0.73 ALDH1A1 (0.39) KDM4EALDH1A1HPGDHSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217045-B2 Organic compounds NOVARTIS AG (CH) 2012-07-10 US disclosed
US-20100113467-A1 Organic Compounds NOVARTIS AG 2010-05-06 US disclosed
EP-2146964-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE Novartis Ag (CH) 2010-01-27 EP disclosed
WO-2008125691-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE NOVARTIS AG (CH) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113467-A1 Organic Compounds SLCO2A1, SLCO1B1, SLCO2B1 PTPN1 3636/4885NR4A1 1950/4885NR4A2 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.